BB-301 — Interim data
2H-2026
Benitec remains on track to provide updated interim clinical study results in 2H-2026Source filing
BNTC biotech catalysts & pipeline
BENITEC BIOPHARMA INC · Data as of 2026-10-25
Upcoming catalysts
BB-301 — Regulatory decision
October
A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in OctoberSource filing
BB-301 — Conference presentation
Oct 27–Oct 30
Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients, at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany, October 27-30, 2026.Source filing